Botanix Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 08/31 22:54

Botanix Pharmaceuticals (ASX:BOT) Full Year 2024 Results

Key Financial Results

  • Net loss: AU$13.9m (loss widened by 52% from FY 2023).
  • AU$0.009 loss per share (further deteriorated from AU$0.008 loss in FY 2023).
earnings-and-revenue-growth
ASX:BOT Earnings and Revenue Growth August 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Botanix Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 25%. Earnings per share (EPS) exceeded analyst estimates by 8.0%.

Looking ahead, revenue is forecast to grow 108% p.a. on average during the next 2 years, compared to a 42% growth forecast for the Pharmaceuticals industry in Australia.

Performance of the Australian Pharmaceuticals industry.

The company's shares are up 11% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Botanix Pharmaceuticals that you should be aware of before investing here.